Telerobotic surgery is moving from isolated demonstrations toward broader clinical and regulatory development, according to a recent MedTech Dive report. The article, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology’s progress and the regulatory and infrastructure questions surrounding remote surgery. It highlighted SS Innovations International (NASDAQ: SSII) alongside larger medical-device companies and emerging robotics developers.
SS Innovations CEO Dr. Sudhir Srivastava, a cardiac surgeon, told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. For SS Innovations, the discussion comes as its SSi Mantra system is accumulating experience in telesurgery while the company seeks to expand into additional international markets. The company reported 195 robotic telesurgeries using its SSi Mantra system as of Sept 28, 2026, including cardiac procedures and long-distance operations. Its installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025, while cumulative procedures reached 14,503. SSi Mantra has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad.
SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand the system into additional international markets. The company’s growing telesurgery experience and regulatory efforts position it in an increasingly relevant part of the surgical robotics market. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. The MedTech Dive article referenced in the report can be accessed through https://ibn.fm/4ZLvL, and additional details are available via Read More>>.
The development matters because telerobotic surgery could extend specialized surgical expertise to remote or underserved areas, but its adoption depends on regulatory approvals and reliable infrastructure. SS Innovations’ progress, including its 195 telesurgeries and expansion into 12 countries, demonstrates that remote procedures are gaining ground. If the company secures FDA clearance and CE marking, it could compete more directly in the U.S. and European markets, where larger medical-device companies already operate. For investors, the company’s installed base growth of 45% and cumulative procedures of 14,503 indicate commercial traction. For the medical field, the outcomes of these regulatory reviews may influence how quickly telerobotic surgery becomes a standard option. MissionIR, a specialized communications platform, distributes updates on companies like SS Innovations through its network, which includes IBN and InvestorWire, offering services such as editorial syndication to 5,000+ outlets and social media distribution.
